Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Br J Dermatol
; 175(2): 340-7, 2016 Aug.
Article
en En
| MEDLINE
| ID: mdl-26989852
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Adalimumab
/
Ustekinumab
/
Etanercept
/
Antiinflamatorios
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Br J Dermatol
Año:
2016
Tipo del documento:
Article